SG11201702805TA - Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents - Google Patents

Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents

Info

Publication number
SG11201702805TA
SG11201702805TA SG11201702805TA SG11201702805TA SG11201702805TA SG 11201702805T A SG11201702805T A SG 11201702805TA SG 11201702805T A SG11201702805T A SG 11201702805TA SG 11201702805T A SG11201702805T A SG 11201702805TA SG 11201702805T A SG11201702805T A SG 11201702805TA
Authority
SG
Singapore
Prior art keywords
fap
combination therapy
chemotherapeutic agents
bispecific antibodies
antibodies specific
Prior art date
Application number
SG11201702805TA
Inventor
Thomas Friess
Oliver Krieter
Meher Majety
Katharina Wartha
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201702805TA publication Critical patent/SG11201702805TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11201702805TA 2014-10-08 2015-10-06 Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents SG11201702805TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14188176 2014-10-08
EP15151221 2015-01-15
EP15160231 2015-03-23
EP15179117 2015-07-30
PCT/EP2015/072974 WO2016055432A2 (en) 2014-10-08 2015-10-06 Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents

Publications (1)

Publication Number Publication Date
SG11201702805TA true SG11201702805TA (en) 2017-05-30

Family

ID=54249506

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702805TA SG11201702805TA (en) 2014-10-08 2015-10-06 Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents

Country Status (14)

Country Link
US (1) US20180064808A1 (en)
EP (1) EP3204412B1 (en)
JP (2) JP6810687B2 (en)
KR (1) KR20170063946A (en)
CN (1) CN106999580B (en)
AU (1) AU2015330087A1 (en)
BR (1) BR112017006468A2 (en)
CA (1) CA2962124A1 (en)
IL (1) IL251203A0 (en)
MX (1) MX2017004526A (en)
RU (1) RU2017116020A (en)
SG (1) SG11201702805TA (en)
WO (1) WO2016055432A2 (en)
ZA (1) ZA201702050B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
WO2010115589A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
MY175341A (en) 2010-08-13 2020-06-19 Roche Glycart Ag Anti-fap antibodies and methods of use
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
JP5768147B2 (en) 2011-02-28 2015-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Monovalent antigen binding protein
KR101638224B1 (en) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 Antigen binding proteins
BR112014032193A2 (en) 2012-06-27 2017-06-27 Hoffmann La Roche bispecific antibody production and combination determination methods, bispecific antibody, formulation and use of bispecific antibody
CA2871882A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
MX2016003593A (en) 2013-10-11 2016-06-02 Hoffmann La Roche Multispecific domain exchanged common variable light chain antibodies.
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
IL284430B2 (en) 2015-01-20 2024-04-01 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
BR112018002570A2 (en) 2015-10-02 2018-10-16 Hoffmann La Roche bispecific antigen binding molecule, bispecific antibody, polynucleotides, ox40-specific binding antibody, pharmaceutical composition and method for inhibiting tumor cell growth in an individual
SG11201811600PA (en) 2016-06-30 2019-01-30 Oncorus Inc Pseudotyped oncolytic viral delivery of therapeutic polypeptides
WO2018111989A1 (en) 2016-12-14 2018-06-21 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
MA48723A (en) 2017-03-10 2020-04-08 Hoffmann La Roche MULTISPECIFIC ANTIBODY PRODUCTION PROCESS
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3917564A4 (en) * 2019-02-01 2022-12-21 NovaRock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
WO2021151005A1 (en) * 2020-01-22 2021-07-29 Ansun Biopharma, Inc. Inhaled das181 to treat cancer in the lung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
DK2483310T3 (en) * 2009-09-29 2014-09-01 Roche Glycart Ag BISPECIFIC DEATH RECEPTOR AGONISTIC ANTIBODIES
EP2519544A1 (en) * 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
MY175341A (en) * 2010-08-13 2020-06-19 Roche Glycart Ag Anti-fap antibodies and methods of use
UA118028C2 (en) * 2013-04-03 2018-11-12 Рош Глікарт Аг Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
RU2015152077A (en) * 2013-05-07 2017-06-13 Ф.Хоффманн-Ля Рош Аг TRIMER ANTIGEN-BINDING MOLECULES

Also Published As

Publication number Publication date
IL251203A0 (en) 2017-05-29
MX2017004526A (en) 2017-06-07
JP2018502822A (en) 2018-02-01
WO2016055432A2 (en) 2016-04-14
RU2017116020A (en) 2018-11-12
EP3204412B1 (en) 2020-08-19
WO2016055432A3 (en) 2016-06-02
CN106999580B (en) 2021-07-06
ZA201702050B (en) 2018-05-30
CN106999580A (en) 2017-08-01
JP2021008476A (en) 2021-01-28
KR20170063946A (en) 2017-06-08
EP3204412A2 (en) 2017-08-16
JP6810687B2 (en) 2021-01-06
CA2962124A1 (en) 2016-04-14
AU2015330087A1 (en) 2017-04-06
BR112017006468A2 (en) 2017-12-19
RU2017116020A3 (en) 2019-04-05
US20180064808A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
ZA201702050B (en) Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
IL282962A (en) Anti-pd-1 antibodies and methods of use thereof
IL304117A (en) Anti-pvrig antibodies and methods of use
HK1259019A1 (en) Anti-pd1 antibodies and methods of use
IL286835A (en) Bispecific tetravalent antibodies and methods of makiing and using thereof
HK1258058A1 (en) Anti-tigit antibodies and methods of use
HK1252857A1 (en) Anti-cd3 antibodies and methods of use
HK1244492A1 (en) Anti-pd-1 antibodies and methods of use thereof
HK1252858A1 (en) Anti-cll-1 antibodies and methods of use
HUE050726T2 (en) Selective reduction of cysteine-engineered antibodies
HK1258850A1 (en) Anti-tpbg antibodies and methods of use